The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Next Oncology; Quironsalud
Leadership - Next Oncology (Inst)
Honoraria - Amunix; Guidepoint Global; IDEAYA Biosciences; Loxo; Puma Biotechnology
Consulting or Advisory Role - Guidepoint Global; OncoArt
Speakers' Bureau - Lilly; Solti
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Incyte (Inst); Janssen (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Menarini (Inst); Merck (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Synthon (Inst); Tesaro (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Bayer; START
Nemvaleukin alfa in patients with advanced renal cell carcinoma: ARTISTRY-1.
 
Emiliano Calvo
Employment - HM Hospitales; START
Leadership - START
Stock and Other Ownership Interests - Oncoart Associated; START
Honoraria - HM Hospitales
Consulting or Advisory Role - Adcendo; Alkermes; Amcure; Amunix; Anaveon; Bristol-Myers Squibb; Janssen-Cilag; Nanobiotix; PharmaMar; PsiOxus Therapeutics; Roche/Genentech; Seagen; Servier; TargImmune Therapeutics
Research Funding - Achilles Therapeutics (Inst); BeiGene; START
Other Relationship - Investigational Therapeutics in Oncological Sciences
 
Valentina Boni
No Relationships to Disclose
 
Arvind Chaudhry
No Relationships to Disclose
 
Philip R. Debruyne
Stock and Other Ownership Interests - Alkermes
Honoraria - Bayer; Bristol-Myers Squibb; Merck/Pfizer; MSD; Roche
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - Janssen
 
Seth D Rosen
No Relationships to Disclose
 
Yan Wang
Employment - Alkermes
Stock and Other Ownership Interests - Alkermes
 
Lei Sun
Employment - Alkermes
Stock and Other Ownership Interests - Alkermes
Patents, Royalties, Other Intellectual Property - Coauthor U.S. Patent Application No: 16/898,008. Compositions and Methods for Cancer Immunotherapy. Coauthor U.S. Patent Application No: 16/897,920. Compositions and Methods for Subcutaneous Administration of Cancer Immunotherapy. (Inst)
Travel, Accommodations, Expenses - Alkermes
 
Monali Desai, MD
Employment - Alkermes
Stock and Other Ownership Interests - Alkermes
 
Rita P. Dalal
Employment - Alkermes; Pfizer (I)
Stock and Other Ownership Interests - Alkermes; Lilly; Merck Sharp & Dohme Oncology; Pfizer (I)
 
Yangchun Du
Employment - Alkermes
Stock and Other Ownership Interests - Alkermes
 
Julie R. Graham
Employment - Alkermes
Stock and Other Ownership Interests - Alkermes
 
Piotr Tomczak, MD
No Relationships to Disclose